Introduction
Methods
Data sources
Search terms
Inclusion criteria
Data collection and analysis
Data synthesis
Results
Study characteristics
Self-reported arthritis
Osteoarthritis
Rheumatoid arthritis
References | Indigenous population | RA classification criteria | Total number of Indigenous participants
N or M:F if available | Control population | Total number of control
N or M:F if available | Features reported |
---|---|---|---|---|---|---|
Studies with comparison group
| ||||||
Jacono [25] | Canadian Aboriginal | ARA (Ritchie) | 5:38 | Caucasian | 53:89 | Demographics, joint distribution, severity (surgical requirements) |
Hitchon [26] | Canadian First Nations | NR; includes some patients not meeting criteria | 143 | Caucasian | 409 | Demographics, patient-reported outcomes |
Poole [27] | American Indian | ACR 1988 | 0:17 | Caucasian | 0:15 | Demographics, patient-reported outcomes |
Genovese [28] | American Indian | NR | 62 | Caucasian | 81 | Demographics, disease activity, joint counts, inflammatory markers, patient-reported outcomes, serology |
Peschken [4] | Canadian Aboriginal | ACR 1987 | 101:380 | Caucasian | 289:1026 | Demographics, joint distribution, disease activity, joint counts, inflammatory markers, patient-reported outcomes, serology |
Hitchon [24] | Canadian First Nations | NR | NR | Non-First Nations | NR | Demographics |
O’Neil [29] | Canadian First Nations | NR | 22:128 | Caucasian | 32:122 | Demographics, joint counts, inflammatory markers, patient-reported outcomes, radiographic findings, serology, severity |
Barnabe [30] | Canadian Aboriginal | NR | 90 | Non-Aboriginal | 1400 | Demographics, disease activity, joint counts, inflammatory markers, patient-reported outcomes, serology, quality of life measures |
Hitchon [24] | Canadian First Nations | NR | NR | Non-First Nations | NR | Demographics, mortality |
Descriptive studies
| ||||||
Templin [31] | American Indian | ACR 1987 | 8:29 | NR | NR | Demographics, disease features, joint counts, patient-reported outcomes, radiographic findings, serology, severity |
Burch [32] | American Indian | NR | 42 | NR | NR | Serology |
Gofton [33] | Canadian Aboriginal | ARA 1958 | 10:4 | NR | NR | Patient-reported outcomes, radiographic findings, serology |
Beasley [34] | American Indian | NR | 17 | NR | NR | Demographics, disease features, radiographic findings, serology |
Willkens [35] | American Indian | ARA and NY Criteria | 0:36 | NR | NR | Radiographic findings, serology |
Harvey [36] | American Indian | Bennett and Wood | 4:10 | NR | NR | Serology |
Harvey [37] | American Indian | ARA 1958 | 3:9 | NR | NR | Demographics, disease features, radiographic findings, serology |
Oen [20] | Canadian Inuit | NR | 6 | NR | NR | Demographics, radiographic findings, serology, severity |
Boyer [38] | Alaska Native | ARA 1958 | 14:33 | NR | NR | Demographics, patient-reported outcomes, radiographic findings, serology |
Jacobssen [39] | American Indian | Rome 1961 | 20:65 | NR | NR | Joint distribution, disease features, serology |
Scofield [40] | American Indian | ACR | 4:41 | NR | NR | Demographics, disease features, serology |
Hirsch [41] | American Indian | ACR and Rome | 88 | NR | NR | Radiographic findings |
Atkins [42] | Canadian First Nations | ARA | 23 | NR | NR | Demographics, disease features, serology |
Coutts [43] | Canadian First Nations | ARA 1987 | 3:14 | NR | NR | Demographics, serology |
Poole [44] | American Indian | ACR 1988 | 0:4 | NR | NR | Demographics, patient-reported outcomes |
El-Gabalawy [45] | Canadian First Nations | ACR | 53:213 | NR | NR | Demographics, serology |
El-Gabalawy [46] | Canadian First Nations | NR | 8:74 | NR | NR | Demographics, serology |
Poole [47] | American Indian | NR | 29 | NR | NR | Demographics, patient-reported outcomes |
El-Gabalawy [48] | Canadian First Nations | ACR 1987 | 14:91 | NR | NR | Demographics, inflammatory markers, serology |
Gaddy [17] | American Indian | ACR | 40 | NR | NR | Demographics, serology |
Ferucci [49] | Canadian First Nations and Alaska Native | ACR 1987 | 11:71 | NR | NR | Demographics, serology |
Barnabe [50] | Canadian First Nations | NR | 19 | NR | NR | Serology |
Rheumatoid arthritis disease characteristics and disease activity
Rheumatoid arthritis patient-reported outcomes
Patient-reported outcome | Study | Finding |
---|---|---|
Health Assessment Questionnaire (HAQ) score (or modified, mHAQ) | Peschken [4] | Mean scores at baseline similar between groups with disease duration <5 years and >15 years but higher in Indigenous groups at last visit (<5 years 0.90 Aboriginal vs 0.67 Caucasian; >15 years 1.21 Aboriginal vs 1.02 Caucasian) Worse scores at baseline (0.72 vs 0.56) and at last visit (1.19 vs 0.86) in Aboriginal for disease duration 5–15 years |
Poole [27] | HAQ score lower in American Indian vs Caucasian patients (1.0 vs 1.4) | |
O’Neil [29] | No differences in mHAQ score at first visit but higher mHAQ scores at last visit in First Nations vs Caucasian patients (0.71 vs 0.42) | |
Templin [31] | HAQ score in American Indian patients of 1.1 at time of study, 1.9 when asked as an ‘ever’ question | |
Poole [44] | HAQ score of 1.8 in American Indian patients, increasing to 2.3 if comorbid diabetes | |
Poole [47] | HAQ score of 1.0 in American Indian patients, increasing to 1.6 if comorbid diabetes | |
Pain (/100) | Genovese [28] | Higher pain score in American Indian vs Caucasian patients (64 vs 54) |
Peschken [4] | Higher pain scores in Aboriginal vs Caucasian patients at all lengths of disease duration (<5 years 50 vs 39; 5–15 years 48 vs 39, >15 years 51 vs 45) | |
Barnabe [30] | Higher pain scores in Aboriginal vs non-Aboriginal patients at biologic start (76 vs 67) | |
Patient Global Score (/100) | Hitchon [26] | Worse score in First Nation patients with early disease and in late disease (43 vs 40) |
Peschken [4] | Worse scores in Aboriginal vs Caucasian patients at all lengths of disease duration (<5 years 45 vs 31; 5–15 years 40 vs 30, >15 years 40 vs 33) | |
O’Neil [29] | No differences in score between First Nations and Caucasian patients at first visit | |
Fatigue (/100) | Peschken [4] | More fatigue in Aboriginal vs Caucasian patients at all lengths of disease duration (<5 years 55 vs 45; 5–15 years 50 vs 45, >15 years 53 vs 49) |
AM stiffness | Genovese [28] | Same duration of morning stiffness between American Indian and Caucasian patients (median 60 min) |
Global Quality of Life (QOL) | Poole [27] | No significant differences between American Indian and Caucasian patients at present, 5 years past or 5 years future |
Component-specific Quality of Life | Poole [27] | No significant differences between Indigenous and Caucasian patients |
EQ5D | Barnabe [30] | After 1 year of biologic treatment worse EQ-5D scores in Aboriginal vs non-Aboriginal patients (adjusted difference −0.07, 95% CI −0.11 to −0.03) |
SF-36 Mental Health Composite Score | Barnabe [30] | After 1 year of biologic treatment worse SF-36 MCS in Aboriginal vs non-Aboriginal patients (adjusted difference −3.59, 95% CI −5.05 to −2.13) |
SF-36 Physical Composite Score | Barnabe [30] | After 1 year of biologic treatment lower SF-36 PCS in Aboriginal vs non-Aboriginal patients (adjusted difference −2.34 (95% CI −3.90 to −0.78) |
Rheumatoid arthritis radiographic findings
Rheumatoid arthritis serology
Rheumatoid arthritis summary
Juvenile idiopathic arthritis
Inflammatory arthritis
Spondyloarthritis
Juvenile spondyloarthritis
Crystal arthritis
Systemic lupus erythematosus
Systemic lupus erythematosus non-renal manifestations (Table 3)
Criteria | Aboriginal, Canada | First Nations, Canada | American Indian | Alaska Native | American Indian/Alaska Native | Australian Aborigine | New Zealand Maori |
---|---|---|---|---|---|---|---|
Photosensitivity | 41 vs 57% [73] | 75% [42] 39 vs 42% [5] | 69% [17] | 39% [57] | 53%# [85] | 14% [82] 11 vs 50%b [86] 11 vs 39%b [87] | NR |
Malar rash | 54 vs 64% [73] | 12.5% [42] 56 vs 50% [5] | 69% [17] | 46% [57] | 32% [85] | 27% [82] 44 vs 83%b [86] | NR |
Discoid rash | 13 vs 20% [73] | 24 vs 25% [5] | 0% [17] | 15% [57] | 8%# [85] | 9% [82] 28 vs 67%b [86] | NR |
Oral ulcers | 49 vs 58% [73] | 38% [42] 17 vs 33% [5] | 32% [17] | 15% [57] | 35%# [85] | 14% [82] 17 vs 50%b [86] | NR |
Serositis | 37 vs 32% [73] | 50% [42] 33 vs 27% [76] Pericarditis 22 vs 12% [5] Pleuritis 25 vs 26% [5] | 38% [17] | 62% [57] | 48% [85] | Pericarditis 32% [82] 22 vs 17% [86] Pleuritis 45% [82] 50 vs 83%b [86] | NR |
Arthritis | 74 vs 82% [73] | 90 vs 82% [5] 90 vs 67%b [77] | 88% [17] | 92% [57] | 80%# [85] | 64% [82] 78 vs 83% [86] 76 vs 90% [87] | NR |
Neurologic | 14 vs 6% [75] | 13% [42] 13 vs 9% [76] Seizures 10 vs 3% [5] Psychosis 10 vs 6% [5] | 32% [17] | 31% [57] | 3% [85] | 5% [82] 6 vs 17% [86] 34 vs 48% [87] | NR |
Hematologic | 60 vs 70% [73] | Leukopenia 70% [42] 33 vs 43% [5] Thrombocytopenia 29 vs 15% [5] Hemolytic anemia 13 vs 4% [5] Lymphopenia 60 vs 65% [5] | 44% [17] | 54% [57] | 90% [85] | Leukopenia 5% [82] 44 vs 33% [86] Thrombocytopenia 32% [82] 39 vs 17%b [86] Hemolytic anemia 9% [82] 14 vs 0% [86] Lymphopenia 64% [82] 77 vs 33%b [86] Anemia 38 vs 31% [87] | NR |
Renal |
Ever
Renal disease 39 vs 40% [73] |
At diagnosis
Proteinuria 22 vs 16% [5] Casts 17 vs 6%b [5]
Ever
Proteinuria 46 vs 25%a [5] Casts 35 vs 12%b [5] Nephritis 48 vs 29% [77] 57 vs 32%b [76] Renal disease 0% [42] |
At diagnosis
Nephritis 21 vs 12% [81]
Ever
Renal disease 32% [17] |
Ever
Renal disease 39% [57] |
Ever
40% [82] |
Ever
Proteinuria 22 vs 17% [86] 62% [82] Casts 11 vs 0% [86] 41% [82] Renal disease 46 vs 28% [87] |
At diagnosis
Nephritis 10 vs 4%b [79]
Ever
Nephritis 17 vs 19% [79]c
|
ANA positive | 96 vs 95% [73] | 88% [42] 100 vs 98% [5] | 69% [17] | 100% [57] | 98% [82] | 100% [82] 100 vs 100% [86] | NR |
Immunologic criteria | 89 vs 83% [73] | 38% [17] | 77% [57] | 61%# [82] | NR |
Systemic lupus erythematosus renal manifestations (Table 3)
Systemic lupus erythematosus serology
Systemic lupus erythematosus disease activity/damage
Systemic lupus erythematosus summary
Juvenile systemic lupus erythematosus
Scleroderma
Diffuse skin involvement | 46.5 vs 35.6% | 64.7% 75.0 vs 66.0% |
Finger contractures | NR | 67.0 vs 72.0% |
Telangiectasias | NR | 92.0 vs 72.3% |
Lung fibrosis | 29.6 vs 33.7% | 88.2% 92.0 vs 57.0%a
|
Pulmonary hypertension | 8.5 vs 11.0% | NR |
Raynaud’s phenomenon | NR | 88.2% 92.0 vs 94.0% |
Digital ulcers | 63.4 vs 52.1% | NR |
Polyarthritis | 44.8 vs 30.5%a
| 83.0 vs 74.0% |
Myositis | 12.7 vs 10.4% | NR |
Scleroderma renal crisis | 4.3 vs 3.9% | NR |
Renal | NR | 0 vs 4% |
Overlap with other disease | 24.3 vs 14.9%a
| NR |
Gastrointestinal symptoms (mean, SD) | 5.8 (3.2) | 4.1 (3.1) |